Karius Gains $100M and FDA Breakthrough Designation for Genomic Pneumonia Test
Karius Inc., a leading company in genomic diagnostics for infectious diseases, announced that its Karius Test has received the FDA's …
All Posts
Sartorius and NVIDIA to Develop AI Models for Stem Cell-Derived Organoids, Reducing Animal Testing in Drug Discovery
Sartorius, a leader in life sciences and bioprocessing, is expanding its collaboration with NVIDIA to enhance the development of innovative …
Nabla Bio Advances Generative Protein Design with $26M Series A Funding
Nabla Bio, a biotechnology firm specializing in generative protein design, has successfully closed a $26 million Series A financing round, …
Recursion Unveils BioHive-2, Fastest Pharma-Owned Supercomputer
Recursion Pharmaceuticals has achieved a significant milestone by completing BioHive-2, reportedly the fastest supercomputer to be wholly owned and operated …
Troubling Safety Data Overshadows Efficacy in MacroGenics' Phase 2 Study
MacroGenics, a biotechnology company, has reported concerning safety outcomes in its phase 2 trial of vobramitamab duocarmazine, a B7-H3-directed antibody-drug …
4 Biotech Startups Developing Breakthrough Drug Modalities
In the dynamic world of drug discovery, companies must continually innovate beyond their existing drug portfolios and modalities. Relying solely …
DeepMind Launches Advanced AlphaFold Model to Enhance Drug Discovery
Google DeepMind has introduced the latest version of its AlphaFold artificial intelligence model, which aims to assist scientists in designing …
The Growing Impact of AI in Healthcare
The advent of artificial intelligence (AI) in healthcare has catalyzed an epoch of change, reshaping diagnostic procedures, therapeutic strategies, and …
Cytomos to Unveil Celledonia™ Technology at London Biotechnology Show 2024
Cytomos, a TechBio company, is gearing up to introduce attendees at the London Biotechnology Show 2024 to its latest development, …
Is AI impacting the Life Sciences real estate market?
Artificial intelligence (AI) is one of the most disruptive technologies the Life Sciences sector has ever seen. It’s having a …
Insilico Medicine Relocates Headquarters to Cambridge, Massachusetts
Insilico Medicine, a clinical-stage company specializing in AI-driven drug discovery, has shifted its corporate headquarters from New York to Boston. …
From Diagnosis to Treatment: The Impact of AI on Rare Disease Drug Development
Drug development for rare (also referred to as orphan) diseases is notoriously challenging. Legislative initiatives, such as the 1983 US …